FDA's Biosimilar Labeling Stance Spurs Preemption Questions
Executive Summary
Whether a biosimilar sponsor may unilaterally make safety-related labeling changes is unclear in light of FDA's decision to require labeling for Sandoz's Zarxio that is almost identical to reference product.